Madsbad S - Search Results

1

Insufficient sleep predicts poor weight loss maintenance after 1 year.

Bogh AF, Jensen SBK, Juhl CR, Janus C, Sandsdal RM, Lundgren JR, Noer MH, Vu NQ, Fiorenza M, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Bogh AF, et al. Among authors: madsbad s. Sleep. 2023 May 10;46(5):zsac295. doi: 10.1093/sleep/zsac295. Sleep. 2023. PMID: 36472579 Free PMC article. Clinical Trial.

2

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

Zander M, Madsbad S, Madsen JL, Holst JJ. Zander M, et al. Among authors: madsbad s. Lancet. 2002 Mar 9;359(9309):824-30. doi: 10.1016/S0140-6736(02)07952-7. Lancet. 2002. PMID: 11897280 Clinical Trial.

3

Early differential defects of insulin secretion and action in 19-year-old caucasian men who had low birth weight.

Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, Vaag AA. Jensen CB, et al. Among authors: madsbad s. Diabetes. 2002 Apr;51(4):1271-80. doi: 10.2337/diabetes.51.4.1271. Diabetes. 2002. PMID: 11916955

4

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

Kjems LL, Holst JJ, Vølund A, Madsbad S. Kjems LL, et al. Among authors: madsbad s. Diabetes. 2003 Feb;52(2):380-6. doi: 10.2337/diabetes.52.2.380. Diabetes. 2003. PMID: 12540611

5

Insulin secretion and cellular glucose metabolism after prolonged low-grade intralipid infusion in young men.

Jensen CB, Storgaard H, Holst JJ, Dela F, Madsbad S, Vaag AA. Jensen CB, et al. Among authors: madsbad s. J Clin Endocrinol Metab. 2003 Jun;88(6):2775-83. doi: 10.1210/jc.2002-021430. J Clin Endocrinol Metab. 2003. PMID: 12788887 Clinical Trial.

6

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Vilsbøll T, et al. Among authors: madsbad s. Regul Pept. 2003 Jul 15;114(2-3):115-21. doi: 10.1016/s0167-0115(03)00111-3. Regul Pept. 2003. PMID: 12832099

7

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.

Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Among authors: madsbad s. Diabetes Care. 2003 Sep;26(9):2581-7. doi: 10.2337/diacare.26.9.2581. Diabetes Care. 2003. PMID: 12941722 Clinical Trial.

8

Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells.

Haugaard SB, Andersen O, Storgaard H, Dela F, Holst JJ, Iversen J, Nielsen JO, Madsbad S. Haugaard SB, et al. Among authors: madsbad s. Am J Physiol Endocrinol Metab. 2004 Oct;287(4):E677-85. doi: 10.1152/ajpendo.00009.2004. Epub 2004 May 18. Am J Physiol Endocrinol Metab. 2004. PMID: 15149949 Free article. Clinical Trial.

9

Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.

Zander M, Christiansen A, Madsbad S, Holst JJ. Zander M, et al. Among authors: madsbad s. Diabetes Care. 2004 Aug;27(8):1910-4. doi: 10.2337/diacare.27.8.1910. Diabetes Care. 2004. PMID: 15277416 Clinical Trial.

10

Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells.

Haugaard SB, Andersen O, Dela F, Holst JJ, Storgaard H, Fenger M, Iversen J, Madsbad S. Haugaard SB, et al. Among authors: madsbad s. Eur J Endocrinol. 2005 Jan;152(1):103-12. doi: 10.1530/eje.1.01835. Eur J Endocrinol. 2005. PMID: 15762193

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

593 results

Search Page